Blog

Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing STONY BROOK, N.Y. September 17, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA events in Boston this week: LineaRx will present its Linea™ IVT […]

– Recurring and Accelerated Receipt of Order Reflects Customer Commitment to Linea DNA –    STONY BROOK, N.Y., September 17, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced it has received a follow-on order valued at more than $500,000 for a quantity […]

Linea™ IVT Platform Delivers All The Benefits of Conventional IVT Without dsRNA Contamination STONY BROOK, N.Y. – July 29, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, will present a poster at the 4th Annual mRNA-based Therapeutics Summit taking place July 29 – 31, 2024, in Boston. The poster […]

via use of the Linea IVT Platform | Chemically-Modified, Enzymatically-Produced IVT Templates + a Next-Generation RNA Polymerase Yuhua Sun | Huan Dong | Qiang Zhao | Finly Philip | Clay Shorrock | Aaron Chung | James Hayward Enter information below to download our poster!

Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand STONY BROOK, N.Y., and JUPITER, FL – June 20, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA […]

– Patent covers the Composition of the Company’s Proprietary Linea™ RNAP, a Core Technology Empowering the Linea™ IVT Platform – – Patent Application Also Currently Pending in Key International Markets –  STONY BROOK, N.Y., – June 5, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in PCR-based DNA […]

STONY BROOK, N.Y., and PRAGUE, Czechia – May 13, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, and the Institute of Hematology and Blood Transfusion (ÚHKT/IHBT) today announced that an abstract relating to the development of a fully enzymatic, non-viral manufacturing workflow to enable the rapid and […]

Award Seeks to Demonstrate Feasibility of Manufacturing mRNA Vaccines in Only 7 Days STONY BROOK, N.Y., April 25, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced the award of a contract from HDT Bio for the purpose of rapid, next-generation vaccine development under a ‘Project NextGen: Enabler’ award to HDT […]

Project To Increase RNAP Manufacturing Capacity and Reduce Unit Costs of Goods Project Slated For Completion Coincident with Company’s Planned Initiation of GMP Manufacturing for Linea™ DNA IVT Templates STONY BROOK, N.Y., and JUPITER, F.L. March 18, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA […]

STONY BROOK, N.Y., March 14, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, will showcase its Linea™ IVT and Linea™ DNA platforms at the 24th Annual World Vaccine Congress, which will be held April 1 – 4, 2024. Applied DNA sales team members will be available during the Congress […]